Effect of Age on Liver Transplantation Recipient Outcomes: Two Centers’ Experience

Khalayleh, Harbi; Imam, Ashraf; Ovadya, Ronli; Aizner, Sigal; Braun, Marius; Safadi, Rifaat; Nesher, Eviatar; Khalaileh, Abed

doi:10.1016/j.transproceed.2022.10.055

Cited by 2 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding the benefit of using organs from donors older than 65 years, the results have been similar to previous studies, as there is no increased risk of recurrence and they provide a similar survival benefit for patients as long as the organs are carefully selected [ 49 , 50 ]. In our cohort, no lower graft survival was identified when the recipients were older than 65 years, although there are studies with mixed results on this aspect, such as that of Lerosey et al, who, in a large follow-up series, found a lower 5-year survival rate in transplanted patients older than 65 years compared to younger patients [ 51 ], while other groups such as Khalayleh et al or Gomez-Navarra et al presented large series in which transplanted patients who were over 65 years of age had similar survival rates [ 52 , 53 ].…”

Section: Discussionmentioning

confidence: 99%

Liver Transplantation for Hepatocarcinoma: Results over Two Decades of a Transplantation Programme and Analysis of Factors Associated with Recurrence

Martínez Burgos,

González Grande,

López Ortega

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Background: In recent years, many studies have attempted to develop models to predict the recurrence of hepatocarcinoma after liver transplantation. Method: A single-centre, retrospective cohort study analysed patients receiving transplants due to hepatocarcinoma during the 20 years of the transplant programme. We analysed patient survival, hepatocarcinoma recurrence and the influence of the different factors described in the literature as related to hepatocarcinoma recurrence. We compared the results of previous items between the first and second decades of the transplantation programme (1995–2010 and 2010–2020). Results: Of 265 patients, the patient survival rate was 68% at 5 years, 58% at 10 years, 45% at 15 years and 34% at 20 years. The overall recurrence rate of hepatocarcinoma was 14.5%, without differences between periods. Of these, 54% of recurrences occurred early, in the first two years after transplantation. Of the parameters analysed, an alpha-fetoprotein level of >16 ng/mL, the type of immunosuppression used and the characteristics of the pathological anatomy of the explant were significant. A trend towards statistical significance was identified for the number of nodules and the size of the largest nodule. Logistic regression analysis was used to develop a model with a sensitivity of 85.7% and a specificity of 35.7% to predict recurrences in our cohort. Regarding the comparison between periods, the survival and recurrence rates of hepatocarcinoma were similar. The impact of the factors analysed in both decades was similar. Conclusions: Most recurrences occur during the first two years post-transplantation, so closer follow-ups should be performed during this period, especially in those patients where the model predicts a high risk of recurrence. The detection of patients at higher risk of recurrence allows for closer follow-up and may, in the future, make them candidates for adjuvant or neoadjuvant systemic therapies to transplantation.

show abstract